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Applicability to Clinical 
Practice 
thanks . . .  
Discussion 
Bronchitis is one of the most common acute infections 
affecting pediatric patients.  Most cases are caused by viral 
infections, do not respond to antibiotic therapy, and can take 
up to 14 days to resolve with supportive therapy.  The 
purpose of this study is to determine if the use of 
Pelargonium Sidoides (Umcka™, EPs 7630) extract will 
decrease the duration and severity of symptoms from acute 
bronchitis in the pediatric population. Pelargonium Sidoides 
abstract is an extract of an African Geranium that has been 
used in traditional medicine for centuries. The review of the 
literature will evaluate multiple randomized controlled trials 
along with other studies that compare placebo, traditional 
supportive therapy and Pelargonium Sidoides extract to 
determine if the use of the extract will decrease severity and 
duration of illness without unacceptable side effects in the 
pediatric population. It has been demonstrated that 
providers will be able to safely advise patients to use 
Pelargonium Sidoides extract without any adverse side 
effects while helping to decrease the severity and duration 
of bronchitis symptoms in children. The finding indicate that 
routine use of Pelargonium Sidoides may give providers an 
alternative, effective and safe treatment that is well accepted 
by patients and caregivers for bronchitis in pediatric 








Will the use of Pelargonium Sidoides in children greater 
than 1 year of age safely and effectively reduce the 
severity and duration of acute bronchitis? 
–Current treatment for acute bronchitis 
• McCance et al.(2010) states that treatment 
consists of rest, humidity, antipyretics, and cough 
suppressants 
–Efficacy of Pelargonium Sidoides 
• Havidvogel et al.(2007) using a BSS after one 
week of treatment demonstrated a decrease of 
4.7 points 
• Kamin et al.(2012) used a BSS system 
demonstrated a decrease of 4.4 points compared 
to placebo of 2.9 
• Kamin et al.(2010) compared dosing of 30,60, 
and 90mg.  The 60mg groups had a decrease 
BSS of 4.4 points and the 90mg group a 
decrease of 5.0 points compared to placebo 
–Safety of Pelargonium Sidoides 
• Kamin et al.(2008) noted 59 adverse events out 
of 200 patients.  A causal relationship was noted 
in 8 events, none cited as serious.  GI upset was 
most prevalent   
• Fau et al.(2003) demonstrated 14 adverse events 
in the treatment group categorized as mild and GI 
upset 
–Mechanism of Action 
• Michaelis et al.(2011) investigated the effects on 
viral replication and demonstrated that 
Pelargonium Sidoides could inhibit replication of 
some viruses 
• Neugebauer et al.(2005) demonstrated increased 
cilary beat frequency after application of a 
solution of Pelargonium Sidoides 
 
 
 Pelargonium Sidoides can be used in addition to the 
usual comfort care in the pediatric population with 
acute bronchitis with very few adverse side effects 
noted in research  
 The research has demonstrated a reduction in 
severity of cough, pulmonary rales, and dyspnea in 
children with acute bronchitis compared to placebo  
 Total daily dosage of 60mg-90mg  
 Begin treatment with Pelargonium Sidoides within 48 
hours of symptom onset   
 Cost of a week long treatment ranges from $10- $15    
 Pelargonium Sidoides is well tolerated by patients 
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Statement of the Problem 
• No known medications reduce the duration or 
severity of acute bronchitis  
• The health care provider has limited options to offer 
these patients as antibiotics have not been found to 
shorten the duration or severity of the illness  
References 
Pelargonium Sidoides is an herbal medication that has 
been used in traditional medicine for centuries.  The 
herbal preparation has recently regained popularity 
especially with patients seeking an alternative to 
traditional medications and treatments.  Pelargonium 
Sidoides is advertised to reduce the duration and 
symptoms of acute bronchitis.  
 
• The best delivery and dosage of Pelargonium 
Sidoides is a liquid solution with 11% ethanol 
dosed at 90mg daily. This has been 
demonstrated in the literature to decrease 
symptom severity earliest in the disease 
process 
• One study used a capsule to administer the 
medication, no comparison was performed to 
determine the best method of delivery 
• All studies used a Bronchitis Severity Score 
(BSS) and included cough, pulmonary rales, 
and dyspnea 
• Decrease in BSS score was greatest in all 
treatment groups compared to placebo 
• Most common adverse events were classified 
under gastrointestinal and were mild 
• No long term studies were performed to 
investigate safety  
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